Purpose: Fungal infections of the central nervous system (CNS) are potentially lethal conditions with high morbidity and mortality. In this review, we summarise the most common clinical manifestations, diagnostic methods, and treatment strategies for intracranial fungal infection at two tertiary care teaching hospitals. Material and methods: Prospective hospital study is carried out at Department of Neurosurgery; Assiut and Suhaj University Hospitals between January2010 to January 2018 (Minimum 12-months follow-up). Radiographs and hospital data of 74 patients with proven intracranial fungal infections were gathered and analyzed. There were no exclusion criteria: age, gender, clinical presentations, immunity status, radiological findings, laboratory, and microbiological data, types of management and outcome. In surgically treated patients, diagnosis was confirmed by pathologic evaluation. Gathered data were coded and entered into a computer and analyzed using SPSS version 22. Results: The greatest number of the patients had 40 to 60 years old (49; 66%) and the mean age was 44 years. There was an overwhelming male patient's ranged preponderance 66%; 49 cases. Sixty-three patients (85%) were immunosuppressed; 11 cases (15%) were immunocompetent. The most common causes of immunosuppression were diabetes 27 patients; 43%, on chemotherapeutic agents 19 patients; 31%, on corticosteroid 16 patients; 25% and AIDS in one patient; 1%. Five different fungal types were identified but Cryptococcus spp. was the most common cause of CNS fungal infection, occurring in 39 patients (53%). This was followed by Candida spp. in 14 patients (19%), Aspergillus in 11 patients (15%), Blastomyces in 7 patients (9%) and Coccidiosis in 3 patients (4%). Headache was the most common presenting symptom, occurring in 33 patients (45%). Other relatively common
Introduction
Fungal infections of the central nervous system (CNS) are rare clinical entities presenting with protean clinical manifestations, difficult diagnostic dilemmas and special therapeutic challenges. The incidence of fungal infections of the CNS has gradually increased in recent years [1] [2] . There appears to be an increasing incidence of invasive fungal infections from 6.6% from 1993 to 1996 to 10.4% from 2001 to 2005 [3] .
This increase in frequency is likely attributed to multiple factors including an aging population, increased use of disease-modifying drugs for treatment of autoimmune disorders, malignancies requiring use of cytotoxic drugs, increased number of bone marrow and solid-organ transplantations requiring long-term use of immunosuppressive agents, and finally, the pandemic spread of HIV/AIDS [4] . Rarely, fungal infection may follow direct inoculation of the brain during intracranial or trans-sphenoidal surgery or following trauma [5] .
Intracranial fungal masses were rarely seen even in major neurosurgical centers in Egypt. Egypt has the largest population among the Middle East and North African countries, but fungal diseases are hardly addressed. No multicenter epidemiology studies have been reported, but the incidence of some fungal diseases in Egyptian population at risk has been reported previously from single centers; M. Khallaf [6] dermatophytosis [7] .
The CNS fungal infections may present with various clinical syndromes which may be specific for certain fungi. Among these, common syndromes are basal meningitis, hydrocephalus, space-occupying lesions (such as cerebral abscesses, granulomas, etc.) stroke syndromes and spinal infections. There are many unanswered and unresolved epidemiological, laboratory, and clinical questions that need to be addressed and understood in the diagnosis, treatment, and prevention of intracranial fungal lesions.
CNS fungal infection is difficult to diagnose because of the paucity of laboratory tests for it and its nonspecific imaging and clinical features. The low rate of fungal isolation from CSF specimens can also confound the diagnostic accuracy in these patients. In general, symptomatic CNS fungal infection carries higher risks of morbidities and mortality as compared to viral, bacterial, or parasitic CNS disorders. An early recognition and an appropriate medical and surgical management strategies are therefore of paramount importance in improving the overall prognosis in CNS infection.
Our challenge is to develop new non-invasive tests for making an early diagnosis. Simultaneously, we urgently need to commit to the development of new antifungal agents that have a broad spectrum of activity, a good safety profile, excellent pharmacokinetic characteristics and a cost that makes them accessible for the treatment of these mycoses.
It is important to understand that intracranial fungal infection represents one of the greatest challenges to public health services, because of their high incidence of morbidity and mortality and financial cost involved in their management. In this review, we summarise the most common clinical manifestations, diagnostic methods, and treatment strategies for intracranial fungal infection at two tertiary care teaching hospitals as such data base is helpful to clinicians and may spur additional efforts to systematically study these uncommon infections. The study was conducted after getting ethical clearance and the permission from Assiut and Suhaj University Teaching Hospital administration. Thorough explanation of the purpose of the study and how data will be treated with respect and confidentiality was provided to the participants. Informed consent according to the criteria set by the local research ethics committee in our Centres had to be obtained in writing before surgery. If consent could not be obtained because the patient was in coma, consent was obtained from relatives.
Patients & Methods

Results
Socio Demographic Data
This prospective hospital based, study was carried out on 74 patients with intracranial fungal infections admitted to Department of Neurosurgery, Assiut and Suhaj University Hospitals between January 2010 and January 2018. Patient demographics are provided in Table 1 . The greatest number of the patients had 40
to 60 years old (49; 66%) and the mean age was 44 years.
There was an overwhelming male patient's ranged preponderance 66%; 49 cases. Sixty-three patients (85%) were immunosuppressed, 11 case (15%) were immunocompetent ( Table 1 ). The most common causes of immunosuppression were diabetes 27 patients; 43%, on chemotherapeutic agents 19 patients; 31%, on corticosteroid 16 patients; 25% and AIDS in one patient; 1% (Table 1) . Table 1 summarizes a variety of clinical syndromes that were seen. Headache was the most common presenting symptom, occurring in 33 patients (45%).
Clinical Data
Other relatively common symptoms were nausea or vomiting 11 patients (15%), fever 10 patients (13%), seizures 9 patients (12%), acute mental status changes 8 patients (11%) and stroke like Symptoms 3 patients (4%). 
Laboratory and Microbiology Data
As displayed in Table 2 , five different fungal types were identified but Cryptococcus spp. was the most common cause of CNS fungal infection, occurring in 39 patients (53%). This was followed by Candida spp. in 14 patients (19%), Aspergillus in 11 patients (15%), Blastomyces in 7 patients (9%) and Coccidiosis in 3 patients (4%) ( Table 2 ). 
Management and Outcome Data
Types of Organism
Identifying the etiological agent as fungal and not bacterial is vital since antibacterial therapy is not effective against fungi and CNS mycoses lead to high morbidity and mortality. Although >100 thousand fungal species are recognized, only a couple of hundred have been suggested to be pathogenic to humans and 10% -15% of pathological fungi produce systemic and/or central nervous system (CNS) mycosis [4] . The common fungal pathogens that cause intracranial infections include Candida, Aspergillus, Mucor, Cryptococcus saccharomycetes, Nocardia brasiliensis, and Histoplasma [10] . Similar findings were noted in our patient population, with 39 patients (53%) with CNS fungal infection attributed to
Cryptococcus. This was followed by Candida spp. in 14 patients (19%), Aspergillus in 11 patients (15%), Blastomyces in 7 patients (9%) and Coccidiosis in 3 patients (4%) ( Table 2 ).
The CNS fungal infections usually result from pulmonary, intestinal, cardiac, or craniofacial mycoses and therefore intracranial seedlings occur either during hematogenous dissemination or by direct extension from the juxta-cranial sites.
Direct contiguous spread to the CNS occurs from the paranasal sinuses, orbits, petro-mastoid region and retro-pharyngeal area in some patients. Direct implantation may result during the period of trauma, intensive care procedures and intracranial operations.
Clinical Presentation
Despite the aggressive nature of these infections, presenting symptoms can be subtle and nonspecific, and even patients with disseminated fungal infection with multiorgan involvement may not present with organ-specific changes or clinical signs. So appreciation of the patient's medical history (maintaining a high degree of clinical suspicion for immunocompromised patients) is the first step to making the correct diagnosis.
Intracranial fungal masses can be seen in any age group but most patients are in the third, fourth and fifth decades of life. Similar findings were noted in our patient population, with the greatest number of the patients had 40 to 60 years old (49; 66%) and mean age was 44 years (Table 1) . There was an overwhelming male patient's ranged preponderance 66%; 49 cases ( [4] . Similar findings were noted in our patient population, with headache being the most common initial clinical presentation in thirty-three patients 45% (Table 1) . Localized form in the macrospore and capsular tissue. Focal infection mainly manifests as granuloma and abscess and is caused by Aspergillus, Candida, zygomycetes, and some species of black fungus [10] .
Rarely, patients with fungal aneurysms (commonly involve the proximal intracranial vessels especially the intradural portion of the internal carotid artery)
are present with subarachnoid hemorrhage [11] . Interestingly, fever is an infrequent symptom in patients with intracranial fungal masses and is seen in only 10% -31% of patients [12] [13]. Similar findings were noted in our patient were fever represented in 10 patients; (13%) ( Table 1) .
CNS fungal granulomas are commonly produced by Aspergillosis, Histoplas- 
Laboratory Investigations
It includes conventional and biochemical examination of the CSF; pathogenic test of the CSF; immunologic test [16] . Galactomannan antigen testing in CSF showed a sensitivity of 88% and a specificity of 96% for CNS Aspergillosis [17] .
CSF antigen testing was found to have a sensitivity of 93% and specificity of 100% for Coccidioidal meningitis [18] . β-D-glucan testing of CSF demonstrated 100% sensitivity and 98% specificity for meningitis caused by E. rostratum [19] .
Imaging
Computed tomography (CT) and magnetic resonance (MR) imaging techniques provide the most meaningful image-based examination of fungal infections, particularly mycotic infection, of the CNS [20] [21] . It can be helpful in determining extra-CNS sources of infection, such as sinusitis or mastoiditis [22] . However Open Journal of Modern Neurosurgery imaging diagnosis should not be considered as a replacement for pathological or microbiological diagnosis as anti-fungal agents are generally toxic and should not be administered on a long-term basis to any patient without definitive diagnosis of a fungal infection.
CT and MRI only reveal intracranial mass or masses that enhance with contrast and can also provide evidence of involvement of the paranasal sinuses and the mastoid sinus. Based on the presence or absence of radiological evidence of paranasal sinus disease; intracranial fungal masses were classified into two types:
rhinocerebral type and purely intracranial type that was further divided into intracerebral or extracerebral forms [23] .
It has been postulated that MR appearances are characteristic for intracranial fungal masses caused by different fungal agents. Cryptococcomas appear as hypointense masses on T2W images whereas Aspergillomas have an intermediate signal intensity on T2W sequences [13] . During growth, abscessed lesions associated with fungal infection display irregular, discontinuous, thick wall ring reinforcements. Some clinicians refer to the "open loop" as the characteristic presentation of intracranial fungal infection [24] .
The commonest location for a primary intracranial fungal masses is the supratentorial compartment with the majority of lesions being present in the frontal lobes followed by temporal lobes. The posterior fossa structures are very infrequently involved especially by isolated infections and may only be occasionally involved when there are several intracranial fungal masses [14] .
Management
There Surgery for intracranial fungal masses can be of different types, namely stereotactic procedures; craniotomy; shunt surgery; and treatment of fungal aneurysms. Generally, radical surgery is advocated for intracranial fungal masses but there is no unanimity regarding the radicality of the excision especially for the rhinocerebral form of the disease. Surgery should always be followed by antifungal therapy for prolonged periods.
Stereotactic Procedures
Stereotactic biopsy/aspiration is resorted to when the intracranial fungal masses is deep seated (e.g. ganglionic, brain stem, thalamus), located in an eloquent region of the brain (e.g. motor regions) or when the masses are multiple and the object of surgery is to arrive at a diagnosis and obtain pus/tissue for culture studies [30] . Stereotactic craniotomies might also be done in patients with intracranial fungal masses to reduce the morbidity of a craniotomy procedure and shorten the duration of the surgery [31] . In our study; stereotactic biopsy was done in 19 patients (deep; located in an eloquent region of the brain or multiple small lesion).
Open Craniotomy
Open craniotomy is performed for suspected intracranial fungal masses that are in relatively accessible regions of the brain and radical excision is feasible and safe. Open surgery is also done often when the diagnosis of intracranial fungal masses is not suspected [13] . In our study; excision was indicated in 38 patients (cortical, relatively accessible regions of the brain). From the literature, there is no conclusive evidence that radical and aggressive surgery improves outcome in patients with intracranial fungal masses but a reasonably radical approach would be advisable whenever it is feasible without severe morbidity or additional neu-Open Journal of Modern Neurosurgery rological deficits [13] .
Shunt
Several authors have documented the need for VP shunts in patients with intracranial fungal masses either as primary procedures or as a secondary procedure when patients with intracranial fungal masses on medical therapy develop hydrocephalus. It is presumed that hydrocephalus in these patients is the result of arachnoiditis of the basal cisterns producing a communicating type of hydrocephalus. CSF shunting was inserted in 17 patients in our series.
Prognosis and Outcome
Despite the introduction of novel agents into the armamentarium of antifungal therapies in the past decade, the incidence of and mortality associated with invasive fungal infections remain far higher than hoped, and these infections continue to pose a challenge for the medical community. High mortality and morbidity have been uniformly reported in almost all series of patients with intracranial fungal masses. The mortality rates range from around 40% in immunocompetent patients to 92% in transplant recipients [14] ; 63% was in Dubey et al. series [13] ; 66.7% in the series reported by Siddiqui et al. [32] and 50% in Njambi [33] 2007, Selby R1997 series [34] . In our series; the mortality rate was 52%. The major cause of mortality and morbidity is the involvement of major cerebral blood vessels by the fungi leading to major strokes. Vasculitis seems to be a frequent sequel to surgery for intracranial fungal masses in the skull base region and several authors have recorded mortality due to stroke following surgery for such lesions [35] . The other reason for poor outcome in immunocompetent patients with intracranial fungal masses is the delay in diagnosis. Finally, some of the mortality and morbidity in patients with intracranial fungal masses is also attributable to the antifungal agents. Amphotericin B is notorious for causing renal and liver failure and has other serious side effects.
There were several important study limitations. The sample size was not large enough to provide strong evidence for clinical practice. CNS fungal infection is difficult to diagnose because of the paucity of laboratory tests for it and its nonspecific imaging and clinical features making it difficult to capture all of the CNS fungal infections seen at our two centers during the study time period. The strength of our study is that it was based on a defined population without selection based on examined, operated and followed up by the authors only as neither neurosurgical treatment nor neurosurgical intensive care was available in other institutions in our area. 
Conclusion
